rethinkTHC Search
Menu
Study breakdown

A 1997 Review Supported Pharmaceutical THC for Nausea and Appetite but Opposed Prescribing Raw Marijuana

ReviewModerate evidence
The takeaway

After reviewing 21 years of research, the authors supported using pure THC formulations for chemotherapy nausea and appetite stimulation but concluded that evidence did not support reclassifying crude marijuana as a prescribable medicine.

Read this if you want to understand the medical establishment's position on medical marijuana at the dawn of state legalization.

Evidence supported THC for nausea and appetite but not crude marijuana as prescribable medicine

What the researchers found

Following the passage of ballot initiatives in California and Arizona making marijuana accessible to patients, the authors reviewed all relevant research from 1975 to 1996 on medical applications of THC and marijuana.

The evidence supported selective use of pure THC preparations for two conditions: nausea associated with cancer chemotherapy and appetite stimulation. Evidence was less convincing for glaucoma and spinal cord spasticity.

However, the authors drew a sharp distinction between pharmaceutical THC and crude marijuana. They cited THC toxicity delivered in any form while supporting its clinical use, and concluded that the evidence did not support reclassifying crude marijuana as a prescribable medicine. They argued for the pharmaceutical pathway (pure, standardized compounds) over the herbal one.

Why it matters

Published in the Annals of Internal Medicine at a pivotal moment when two states had just passed medical marijuana ballot initiatives, this review represented a mainstream medical position that supported therapeutic cannabinoids but opposed crude marijuana prescribing. This distinction between "medicine" and "marijuana" shaped the medical establishment's response to the growing medical cannabis movement.

The numbers in context

Twenty-one years of research reviewed (1975-1996). Two supported therapeutic applications: chemotherapy nausea and appetite stimulation. Two insufficient applications: glaucoma and spasticity.

How the study worked

Literature review of research published between 1975 and 1996 on medical applications of delta-9-THC and crude marijuana, covering nausea, glaucoma, appetite stimulation, and spasticity. Legal precedents were also reviewed.

What this study cannot tell us

The review was explicitly positioned against crude marijuana reclassification, which may have influenced the framing of evidence. Published before the wave of clinical trials on whole-plant cannabis that followed state legalization. The "toxicity" framing did not include comparison with other approved medications' risk profiles.

How to read the evidence

A narrative review in a prestigious medical journal. Authoritative synthesis but reflecting a specific policy position that has been contested by subsequent evidence.

When this study was published

Published in 1997, shortly after California and Arizona passed medical marijuana ballot initiatives. The medical cannabis evidence base has expanded enormously since.

The bigger picture

This review captures a position that has become less common over time. As more states legalized medical marijuana and whole-plant products demonstrated utility that single molecules did not fully replicate (the "entourage effect"), the sharp distinction between pharmaceutical THC and crude marijuana became more contested.

Questions still open

  • Has subsequent evidence changed the case for crude marijuana as medicine? Does whole-plant cannabis offer advantages over pure THC that this review did not consider? How has the medical establishment's position evolved since 1997?

Common questions

Did the review support medical cannabis?
It supported pharmaceutical THC (like dronabinol) for chemotherapy nausea and appetite stimulation, but opposed reclassifying crude marijuana as a prescribable medicine.
What conditions had evidence?
Nausea from chemotherapy and appetite stimulation had the strongest evidence. Glaucoma and spasticity evidence was considered insufficient.

Read the original research

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.

Annals of internal medicine, 126(10), 791-8

Citation

Voth, E A; Schwartz, R H. (1997). Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.. Annals of internal medicine, 126(10), 791-8.

Explore the wider topic